<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> is commonly associated with EBV <z:e sem="disease" ids="C0872054" disease_type="Disease or Syndrome" abbrv="">latent infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence of EBV reactivation (active <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> with replicative cycle) was evaluated in a series of 30 patients with untreated <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (except for one case with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>) by quantitation of EBV DNA and titration of anti-ZEBRA antibodies in serum samples </plain></SENT>
<SENT sid="2" pm="."><plain>DNA was detected in serum (&gt;2.5 x 10(2) genomes/ml) in 15 of 30 patients and was more frequent in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> with EBV-positive Reed-Sternberg cells (10/12) than in EBV-negative cases (5/18), (P&lt; 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>Of interest was the demonstration that <z:e sem="disease" ids="C0042749" disease_type="Disease or Syndrome" abbrv="">viremia</z:e> correlated well with increased titers of anti-ZEBRA IgG and/or standard serological profiles of EBV reactivation (12/15), (P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>However the lack of EBV replicative cycle in Reed-Sternberg cells (negative for ZEBRA antigen and early antigen BHLF1) suggests that the <z:mp ids='MP_0001799'>viral</z:mp> replication occurs in a nonneoplastic cell compartment rather than in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>The measurement of EBV DNA loads and the titration of anti-ZEBRA antibodies shed new lights on the link between activation of EBV replication and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>: these serological markers together with the determination of the EBV status of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suggest that replication of the <z:mp ids='MP_0001799'>viral</z:mp> genome occurs with a decreased efficiency of the immune system, thus allowing progression of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>